[8] The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, with no new safety signals over a mean follow-up of 34.2 months
It also stimulates insulin secretion by the pancreas, effectively lowering blood sugar levels
At Body Balance Medical in Las Vegas, Mia LoPreiato, NP , Biote-certified, works with men who are exactly where you are: informed, motivated, and stuck
Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al
This is why many obesity researchers view retatrutide as a significant advancement in the evolution of weight loss medications